If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is tirzepatide indicated for patients with type 1 diabetes?
Lilly has not studied tirzepatide in people with type 1 diabetes and it is not indicated for use in patients with type 1 diabetes.
See important safety information, including boxed warning, in the attached prescribing information.
Use in Patients With Type 1 Diabetes
Tirzepatide is not indicated in people with type 1 diabetes (T1D).1
Lilly Clinical Studies
There is no information on the use of tirzepatide in people with T1D because patients with T1D were excluded from tirzepatide clinical trials.1-5
Non-Lilly Studies
There is an ongoing phase 2 study, not sponsored by Lilly, titled "Tirzepatide for the treatment of concurrent type 1 diabetes and overweight or obesity: a placebo-matched randomised controlled trial."6
Enclosed Prescribing Information
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
3Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X
4Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. https://doi.org/10.1038/s41591-023-02597-w
5Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://doi.org/10.1001/jama.2023.24945
6Tirzepatide for the treatment of concurrent type 1 diabetes and overweight or obesity: a placebo-matched randomised controlled trial. ClinicalTrials.gov identifier: NCT06180616. Updated June 3, 2024. Accessed September 25, 2024. https://clinicaltrials.gov/study/NCT06180616
Date of Last Review: October 02, 2024